Morales, EnriqueRúa Figueroa, IñigoCallejas Rubio, José LuisÁvila Bernabéu, AnaBlanco Alonso, RicardoCid Xutglà, M. CintaManrique Escola, JoaquínNarváez García, Francisco JavierSopeña, BernardoQuintana Porras, Luis F.Romero Yuste, SusanaSolans Laqué, Roser2025-04-252025-04-252025-010211-6995https://hdl.handle.net/2445/220652Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is characterised by small vessel necrotising inflammatory vasculitis. Prior to immunosupressant therapy availability it usually led to a fatal outcome. Current treatment has changed ANCA-associated vasculitis into a condition with a significant response rate, although with a not negligible relapse occurrence and cumulative organ lesions, mostly due to drug-related toxicities. The use of glucocorticoids, cyclophosphamide and other immunosupressants (such as azathioprine, mychophenolate and methotrexate) was optimised in a series of clinical trials that established the treatment of reference. In recent years, a better knowledge of B lymphocyte function and the role of complement inhibition has transformed the course of this disease while minimising treatment-related adverse effects. This multidisciplinary document of recommendations is based on the consensus of three scientific societies (Internal Medicine, Nephrology and Rheumatology) and on the best available evidence on diagnosis, treatment and follow-up of patients with ANCA-associated vasculitis, including some special situations. The aim of this document is to provide updated information and well-grounded clinical recommendations to practising physicians as to how to improve the diagnosis and treatment outcome of our patients.44 p.application/pdfspacc-by-nc-nd (c) Morales, Enrique et al., 2025http://creativecommons.org/licenses/by-nc-nd/4.0/NeutròfilsImmunosupressióAutoanticossosInflamacióVasculitisNeutrophilsImmunosuppressionAutoantibodiesInflammationVasculitisinfo:eu-repo/semantics/article7526132025-04-25info:eu-repo/semantics/openAccess